Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

Memantine has shown cognitive, functional, and behavioural benefits in Alzheimer's disease (AD) studies. An 8-week, randomised, double-blind study in patients with moderate to severe AD (DSM-IV -TR criteria and an MMSE ≤ 18) assessed the tolerability of switching AD patients, in whom there was doubt about the continued efficacy of donepez...More